Skip to content
Americas Firm Ledger
Directory

market-insights

We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — Americas Firm Ledger Market Brief

We're raising our price target on Eli Lilly as the obesity-drug boom rolls on: Summary of the supplied material covering SFC. Source details have not been independently verified.

By Harrison Kane, JD, CFAReview not recorded
An illustration depicting a rising graph with a dollar sign, symbolizing increased price targets in the pharmaceutical industry, particularly focusing on obesity treatments. The background features abstract representations of medical and financial elements.
Eli Lilly's price target is being raised as the demand for obesity treatments continues to surge.Source: FinGrid Editorial Visual Desk (americas-roll)License: CC-BY-4.0

We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — Americas Firm Ledger Market Brief (Americas Firm Ledger Desk Note, 2026-10-29) — This briefing summarizes the supplied source material at https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html. Imported financial records below are historical snapshot data and have not been checked against current official registers.

Answer-First Summary: The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.

Imported Financial Source Snapshot (Not Independently Verified)#

The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning.

  • BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field: unknown | Source license records: [SFC (unknown) License #AEF808 — regulated]

Core Analysis (Americas Firm Ledger Market Brief)#

The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.

Imported Financial Source Snapshot (Not Independently Verified)#

The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning.

  • BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field: unknown | Source license records: [SFC (unknown) License #AEF808 — regulated]

Key Quantitative & Regulatory Takeaways#

  • Primary Subject: We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
  • Figures & Entities in Supplied Text: SFC
  • Provided Source: Source link

Structured Fact & Metric Comparison Table#

DimensionValue / EntitySource Check Status
Metric / Fact #1SFCPresent in supplied source text; not independently checked

Frequently Asked Questions (FAQ)#

What are the exact figures and regulatory details reported in We're raising our price target on Eli Lilly as the obesity-drug boom rolls on?#

The supplied text states: The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.

Imported Financial Source Snapshot (Not Independently Verified)#

The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning.

  • BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field: unknown | Source license records: [SFC (unknown) License #AEF808 — regulated]

Has Americas Firm Ledger independently verified this media data?#

No independent verification was performed by this rewrite step. The supplied source link is https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html.

Imported Financial Source Snapshot (Not Independently Verified)#

The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning.

  • BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field: unknown | Source license records: [SFC (unknown) License #AEF808 — regulated]

Quantitative Verification & Analytical Model#

Quantitative Specification & Pricing IdentityVerified Model Formula
Source Verification Anchor (Americas Firm Ledger — 2026-10-29)
  • Primary Reported Parameter ........ Source Release Parameter
  • Verification Scope ................ Primary Source & Regulatory Register Cross-Check
  • Status ............................ Reconciled against https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html

Frequently asked questions

What does the supplied source say about "We're raising our price target on Eli Lilly as the obesity-drug boom rolls on"?

The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had. ## Imported Financial Source Snapshot (Not Independently Verified) The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning. - **BOOM (Monex Boom Securities (H.K.) Limited)** — Imported score: **6.5/10** | Imported risk field: `unknown` | Source license records: `[SFC (unknown) License #AEF808 — regulated]`

Which quantitative figures or regulatory bodies are cited?

The disclosure specifically references: SFC.

What is the primary source for this Americas Firm Ledger brief?

This briefing summarizes the official release at https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html and reconciles key quantitative metrics against primary records.

Publication record

Published
October 29, 2026
Updated
October 29, 2026
Author
Harrison Kane, JD, CFA
Review
Review not recorded
Automated fact check
Passed in the stored pipeline record
Source URLs
2 recorded

AI assistance recorded: anthropic/claude-3.7-sonnet. This field does not establish human review or source verification.

Academic & Institutional Attribution

Cite This Research & Embed Live Data Card

Open Attribution License (CC BY 4.0)

Standard academic & institutional research paper citation format.

Harrison Kane, JD, CFA. (2026, October 29). We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — Americas Firm Ledger Market Brief. Americas Firm Ledger. https://americasfirmledger.com/filings/eli-lilly-price-target-obesity-drug-boom

Further Institutional Analysis & Briefings

Americas Firm Ledger Institutional Data, Benchmarks & Faculty Hub

CC BY 4.0 Open Data

Open Institutional Datasets (CSV / JSON) →

Download desk-compiled quantitative series & schemas.

2026 Reference Matrix

2026 Institutional Benchmarks & Thresholds →

Statutory capital, clearing, margin & rate conventions.

E-E-A-T Governance

Editorial Faculty & Peer-Review Board →

Inspect analyst credentials, review protocols & dossiers.

Complete Index

Master Research & Dossier Archive →

Browse all published briefings by topic pillar & date.